Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,475
Out of 4,479 analysts
12
Total ratings
10%
Success rate
-55.85%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.04 | +163.16% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $4 | $0.55 | +632.60% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $1.07 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $7.41 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $1.09 | +13,661.47% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.08 | +386.54% | 1 | Jun 29, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $18 | $0.74 | +2,327.84% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.88 | +3,427.94% | 1 | May 18, 2022 | |
| DRMA Dermata Therapeutics | Initiates: Buy | $3,360 | $2.29 | +146,624.89% | 1 | Sep 21, 2021 | |
| ONCT Oncternal Therapeutics | Initiates: Buy | $320 | $7.02 | +4,461.65% | 1 | Mar 30, 2021 |
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.04
Upside: +163.16%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $4
Current: $0.55
Upside: +632.60%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.07
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $7.41
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $1.09
Upside: +13,661.47%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.08
Upside: +386.54%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $18
Current: $0.74
Upside: +2,327.84%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.88
Upside: +3,427.94%
Dermata Therapeutics
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $2.29
Upside: +146,624.89%
Oncternal Therapeutics
Mar 30, 2021
Initiates: Buy
Price Target: $320
Current: $7.02
Upside: +4,461.65%